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ABSTRACT
Objectives: An assessment of implantation efficacy and safety of self-developed self-expanding stent  in patients with 
an ovarian cancer induced by intestinal obstruction. 
Material and methods: The study of the stenting efficacy and safety was realized prospectively. The group consisted 
of 13 patients with left half colon obstruction due to an inoperable metastatic ovarian carcinoma. All the patients had 
a histopathologically diagnosed ovarian carcinoma and were treated in the past both surgically and systemically. Stenting 
was preceded by a Computed Tomography (CT) scan confirming and locating the obstruction. Patients with a multilevel 
intestinal obstruction were disqualified.
Results: Nine stents were implanted in the rectosigmoid; 4 stents were implanted in an externally compressed rectum. 
One migration of implanted stent was observed. In one case 2 stents were implanted due to an insufficient coverage of the 
stricture. The decompression of the obstruction of the gastrointestinal tract was achieved in 11 patients (85%).
Conclusions: 1) The implantation of our own developed, self-expanding stent is effective and safe. 2) The implantation of 
the stent in patients with an inoperable ovarian cancer causing an obstruction of the gastrointestinal tract is an effective 
procedure limiting postoperative complications and improving life comfort by avoiding stoma.
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INTRODUCTION 
The obstruction of the gastrointestinal tract in an ad-
vanced ovarian carcinoma is common. During the last six 
months of their life, about 31% of patients are hospitalized 
due to an intestinal obstruction [1]. In the past, the com-
monly choosen treatment was surgery, often resulting in 
a colostomy or ileostomy. A surgical treatment of intesti-
nal obstruction in patients with a recurrent ovarian cancer 
often results in complications 22%, including abscesses, 
peritonitis, intestinal fistulas, as well as a 6% perioperative 
mortality rate [1]. 
A description of an intestinal stent implantation was 
first published by Dohmoto in 1990 [2]. He used a metallic 
endoprosthesis to restore intestinal patency in a patient 
with an inoperable rectal carcinoma. Tejero et al. described 
the use of an enteral stent in a patient with an operable 
recital carcinoma, although with concomitant obstruc-
tion [3]. It was the first application of an enteral stent to 
decompress the intestine and to prepare the patient for 
surgical resection. 
Modern prostheses are made of light metal alloys, come 
in various sizes and have different physical properties. Re-
viewing 88 clinical trials 92% stent implantations were suc-
cessful, accompanied by an intestinal decompression within 
72 hours [5].
The development of endoscopic techniques and tech-
nological progress in the construction permitted the use 
of nickel titanium alloy (nitinol) stents. A characteristic fea-
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ture of nitinol stents is the possibility to obtain various 
degrees of dilatation, thus allowing their use both in the 
upper (oesophagus, stomach and duodenum) and lower 
gastrointestinal tract (large intestine). Beside the material 
used, stets also differ in construction. 
OBJECTIVES 
The aim of this study is to assess the efficacy and safety 
of the implantation of our own developed self-expanding 
enteral stent in patients with a cancer-induced obstruction 
of the left half of the colon due to an ovarian carcinoma. 
MATERIAL AND METHODS 
Between 2012 and 2014 thirteen patients with inop-
erable left half colon obstruction and rectum caused by 
a compression due to ovarian carcinoma were classify for 
examinations (Tab. 1). A CT scan permitted to locate the 
obstruction and plan the length of the stent. General Elec-
tric LightSpeed Ultra CT Scanner was used by Diagnostic 
Department for examination. The results were evaluated by 
experienced radiologists. The study included patients with 
inoperative ovarian cancer which causes obstruction on one 
level in an episode of distal segment of rectal colon. Patients 
revealing symptoms of a multilevel enteral obstruction were 
excluded from the trial.
The Bioethics Committee at the Medical University of 
Warsaw approved the stents for implantation (KB 42/2012).
Our measurements of the neoplasm’s stricture on the 
basis of a CT scan prior to surgery and a comparison of 
its dimensions with a histopathological analysis indicated 
that our stent should cover only the internal length of the 
neoplasm. This is an innovative approach, as classical enteral 
stents, besides the main tube expanding the neoplasm, also 
feature flared distal and proximal ends, distinctly exceeding 
the lumen of the malignancy. They are part of the stent’s 
anti-migratory system. They drift in the healthy lumen of the 
intestine irritating and damaging the mucous membrane 
of the distal intestine and, after laxation, also the intestine 
upstream of the stricture.
For this reason, our stent lacks these anti-migratory 
flared ends. However, the lack of such system may expose 
the stent for more frequent migrations. For this reason, 
we designed a proprietary and unprecedented system of 
hooks ensuring a permanent anchoring of the stent in the 
neoplasm’s mass. They are located in the central section, on 
the facing sides. The length of the hooks was designed to 
prevent the risk of an intestinal perforation, while maintain-
ing the stent securely in the location of the obstruction. On 
the basis of a perioperative assessment of the intestine’s 
thickness in the location of the neoplasm in 50 patients, 
it was determined, that the minimum thickness varied be-
tween 5 mm and 4.7 cm. The developed stent’s hooks were 
3 mm in length. This is a safe length, not causing perfora-
tions and sufficient to ensure its secure anchoring in the 
intestine’s wall (Fig. 1) 
To implant safely the stent in the obstruction it must 
be clearly seen in X-rays. The visibility were tested by tak-
ing X-ray images of various weave densities stents (Fig. 2). 
Since the implantation of a stent in the lumen of the bowel 
is a dynamic process with a constantly changing background 
resulting from the bowel’s motility and respiratory move-
ments, the stent’s visibility was enhanced by installing mark-
ers with more enhanced X-ray visibility at the distal and 
proximal ends. 
The examination was conducted in Endoscopic Labora-
tory of the Department of  Metabolic Diseases and Gastro-
enterology Institute and Nutrition in Warsaw by experienced 
team using the TIMKO Ziehm solo X-ray model. The pro-
cedure was performed in sedation. Intestinal obstruction, 
advanced ovarian cancer and comorbidities eligible patients 
for anesthesia stage IV ASA. Endoscopic procedure begins 
with the placing the colonoscopy depending on stenosis 
localization. The tool is placed with minimal insufflation of 
air near the stenosis. Through the working channels rigid 
guide searching tumor stenosis is carried. Along the guide 
the catheter is assumed beyond the tumor and the contrast 
is given to ensure right direction of  implantation and lack 
of perforation (Fig. 1–3). Subsequently  the length of the 
stent is confirmed by measuring the distance between the 
tumor distal edge and colonoscopy driven as close as pos-
sible to the tumor. Savary-Gilliard dilators are placed along 
the guide through the channel with the catheter. Exten-
sion is carried out to reach the tumor diameter for easily 
carrying out the set beyond stenosis. The next step is the 
intestinal stent implantation. The first step is to  placed the 
set beyond tumor under fluoroscopic control. The balloon 
on the end of the stent is expanded, filled with contrast and 
changes the position towards the tumor. The deformation 
of the balloon is a signal of the distal stenosis position and 
is also the moment of releasing the stent. The procedure is 
Figure 1. Stent construction
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performed under radiological control so the position of the 
stent can be observed. The efficacy of the stent’s implanta-
tion was assessed postoperatively during a colonoscopy 
(Fig. 3). The restoration of the gastrointestinal tract’s patency 
was assessed over a 24-hour period, based on physical ex-
amination and case history. Three patients were subjected to 
a 3-month observation, 7 patients to a 5-month observation, 
and 3 patients to a 12-month observation. The length of the 
observation depended of the patient’s general condition. 
Upon completion of implantation balloon is emptied and 
the entire set is removed  from the intestinal lumen.
RESULTS
Nine stents were implanted in the sigmoid and rectosig-
moid sections; 4 stents were implanted in the externally 
compressed rectum. All patients were evaluated for the ef-
fectiveness of decompression obstruction 12 and 24 hours 
after the treatment. In addition to the physical examination 
the X-ray scan of the abdomen was performed to determine 
the degree of radiological obstruction reduction and assess 
the position of the implanted stent. The restoration of pa-
tency of the gastrointestinal tract and the correct position 
of the stent was consider as good result. A single implanted 
stent’s migration was observed. The patient underwent 
a colostomy. The decompression of the obstruction of the 
gastrointestinal tract was obtained in 11 patients (85%) 
after the first stent implantation. In one case 2 stents were 
implanted due to an insufficient coverage of the stricture. 
Partial resolution of symptoms and withholding of stool 
was an indication for repeating the treatment during which 
a second stent was implanted with good clinical effect.
DISCUSSION
The cause of intestinal obstruction in the ovarian cancer 
is tumor oppressive intestinal lumen  or tumor spread to the 
peritoneum causing functional impairment of motor skills 
due to the infiltration of the mesentery and running her 
nerves associated with motor activity. It is estimated, that in 
the case of a colorectal cancer, obstruction occurs in 10% to 
28% of cases, and during the treatment of an ovarian carci-
noma, it occurs in 20% to 50% of patients [1–3]. In patients 
with advanced ovarian carcinoma, enteral obstruction is 
an insidious process developing over weeks and yielding 
to a spontaneous remission under therapy between succes-
sive obstructive interludes. This is the most frequent form 
of the so-called enteral sub-obstruction, and it is caused by 
multifocal metastases to the colon wall. Local forms of ad-
vanced ovarian cancer are rare and most frequently located 
in the minor pelvis, where the pressure of the neoplastic 
mass compresses the sigmoid or the rectum. Previous pro-
cedures consisted in a surgical opening of a stoma above 
the obstruction. For a patient with a advanced ovarian car-
cinoma, despite being performed due to vital indications, 
it remains a major physical handicap, very often leading 
to death during the postoperative period. Surgical treat-
ment is recommended only for patients with an obvious 
impediment, visible in a CT scan, and inaccessible for en 
endoscopic prosthesis. Several control trials focus on the role 
of endoscopic prosthesis insertion in the intestinal lumen as 
palliative treatment of an obstruction caused by a regional 
carcinoma recurrence and the ovarian cancer in particular 
[4–7]. Contrary to other indications regarding colorectal, 
stomach and esophageal cancer, in the case of ovarian car-
cinoma, the insertion of enteral prostheses is a procedure 
marked with a high rate of technical success, reaching be-
tween 78.8% and 100%, as well as a clinical efficacy factor 
between 83% and 100%. [8, 9]. When the clinical success 
factor is concerned, it was irrelevant if the obstruction was 
due to an infiltration of the primary neoplasm, or its metas-
tasis to the minor pelvis (carcinomatosis) [10, 11]. Classic 
enteral stents were first used in 2009. On the basis of our 
own experience regarding the implantation of stents due 
to a carcinoma of the large intestine, we decided to develop 
our own enteral stent. In 2011 the proces begun and the 
manufacturer of the first Polish enteral stent was the Balton 
Figure 2. Visibility of stent in X-rays
Figure 3. Implanted stent
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company. The increasing number of patients with an gas-
trointestinal tract obstruction and unsatisfactory surgery 
results resulted in the introduction of the lightly invasive 
endoscopic technique to restore patency in strictures. When 
developing our own stent, we audited the design of stents 
from leading manufacturers worldwide. The goal was to 
use the best materials and to eliminate the shortcomings of 
stents available on Polish market. The most frequent compli-
cation in stricture stenting is migration. It occurs in 4.4% to 
11.8% of cases. In our material we dealt with one migration 
that is 7.7%. The  migration was due to an excessive dilata-
tion of the neoplasm’s lumen with a Savary-Gilliard Dilator 
device. The stent achieves its full expansion after 24 hours 
and then it is fully anchored in the neoplasm’s mass.  The 
second complication which occurred after 4 months, was 
an outgrowth of the neoplasm beyond the upper edge of 
the stent and a subsequent stricture of the intestine’s lu-
men. In this case we implanted an additional stent above 
the first one covering the neoplasm’s mass. This single point 
rectal stricture was due to peritoneal metastasis. Until now, 
such diagnosis was a contraindication for a stent implant. 
However, a review of current texts shows that stenting is 
an acceptable solution in such case [12, 13].
The main use of stent was a cancer-induced obstruc-
tion due to a colorectal carcinoma. In this cases, the stent 
was affixed in the narrowed, solid mass of the neoplasm. 
It appears that a healthy bowel wall or muscosa externally 
pressed positions the stent correctly in the lumen. One 
stent migrated. The reason was its very low positioning 
in the rectal lumen caused by a mechanical failure of the 
stent’s expanding system. The female patient was qualified 
for a stomy. The extent of a neoplasm’s restriction of the 
enteral lumen is easy to assess on the basis of a CT scan, 
as well as during surgery in the case of a colorectal carci-
noma. In the case of an externally applied pressure, when 
the mucous membrane of the bowel is regular, the extent 
will not be visible in an endoscopy during the procedure. 
In this case, the best solution is to implant the stent under 
CT control. We have performed such a procedure following 
the incomplete coverage of the stricture during the classical 
procedure. The additional stent was implanted above the 
one previously implanted (Fig. 3). In conclusion, the endo-
scopic stent implantation in a cancer-induced obstruction 
due to a gynecological carcinoma is very effective. A pal-
liative stenting for the treatment of obstructions is a good 
alternative to surgical treatment. 
CONCLUSIONS 
The implantation of our own developed, self-expanding 
stent is effective and safe 
The implantation of a stent in patients with an inoper-
able ovarian cancer causing an obstruction of the gastroin-
testinal tract is an effective procedure limiting postopera-
tive complications and improving life comfort by avoiding 
stoma.
ACKNOWLEDGEMENTS
We thank Balton Sp. z o.o. for assistance in creating stent.
REFERENCES
1. Baron TH. Colonic stenting: a palliative measure only or a bridge to 
surgery? Endoscopy. 2010; 42(2): 163–168, doi: 10.1055/s-0029-1243881, 
indexed in Pubmed: 20140833.
2. Dohmoto M, Hünerbein M, Schlag PM. Application of rectal stents for 
palliation of obstructing rectosigmoid cancer. Surg Endosc. 1997; 11(7): 
758–761, doi: 10.1007/s004649900444, indexed in Pubmed: 9214327.
3. Tejero E, Mainar A, Fernández L, et al. New procedure for the treatment 
of colorectal neoplastic obstructions. Dis. Colon Rectum. 1994; 37(11): 
1158–1159, doi: 10.1007/bf02049822, indexed in Pubmed: 7956588.
4. Keswani RN, Azar RR, Edmundowicz SA, et al. Stenting for malignant co-
lonic obstruction: a comparison of efficacy and complications in colonic 
versus extracolonic malignancy. Gastrointest. Endosc. 2009; 69(3 Pt 2): 
675–680, doi: 10.1016/j.gie.2008.09.009, indexed in Pubmed: 19251009.
5. Shrivastava V, Tariq O, Tiam R, et al. Palliation of obstructing malignant 
colonic lesions using self-expanding metal stents: a single-center 
experience. Cardiovasc Intervent Radiol. 2008; 31(5): 931–936, 
doi: 10.1007/s00270-008-9328-2, indexed in Pubmed: 18379839.
6. Jost RS, Jost R, Schoch E, et al. Colorectal stenting: an effective therapy 
for preoperative and palliative treatment. Cardiovasc Intervent Radiol. 
2007; 30(3): 433–440, doi:  10.1007/s00270-006-0012-0, indexed in 
Pubmed: 17225973.
7. Watt AM, Faragher IG, Griffin TT, et al. Self-expanding metallic stents for 
relieving malignant colorectal obstruction: a systematic review. Ann. 
Surg. 2007; 246(1): 24–30, doi:  10.1097/01.sla.0000261124.72687.72, 
indexed in Pubmed: 17592286.
8. Small AJ, Coelho-Prabhu N, Baron TH. Endoscopic placement of self-
-expandable metal stents for malignant colonic obstruction: long-term 
outcomes and complication factors. Gastrointest. Endosc. 2010; 71(3): 
560–572, doi: 10.1016/j.gie.2009.10.012, indexed in Pubmed: 20189515.
9. Köhler G, Antoniou SA, Lechner M, et al. Stenting for Emergency Colo-
rectal Obstruction: An Analysis of 204 Patients in Relation to Predictors 
of Failure and Complications. Scand J Surg. 2015; 104(3): 146–153, 
doi: 10.1177/1457496914552342, indexed in Pubmed: 25260783.
10. Caceres A, Zhou Q, Iasonos A, et al. Colorectal stents for palliation of 
large-bowel obstructions in recurrent gynecologic cancer: an updated 
series. Gynecol. Oncol. 2008; 108(3): 482–485, doi:  10.1016/j.ygy-
no.2007.11.035, indexed in Pubmed: 18190953.
11. Rubin SC, Hoskins WJ, Benjamin I, et al. Palliative surgery for intestinal ob-
struction in advanced ovarian cancer. Gynecol. Oncol. 1989; 34(1): 16–19, 
doi: 10.1016/0090-8258(89)90097-8, indexed in Pubmed: 2472311.
12. Kim JiW, Jeong JiB, Lee KL, et al. Comparison of clinical outcomes be-
tween endoscopic and radiologic placement of self-expandable metal 
stent in patients with malignant colorectal obstruction. Korean J Ga-
stroenterol. 2013; 61(1): 22–29, doi: 10.4166/kjg.2013.61.1.22, indexed 
in Pubmed: 23354346.
13. Aadam AA, Martin JA. Enteral stents in malignant bowel obstruction. 
Gastrointest. Endosc. Clin. N. Am. 2013; 23(1): 153–164, doi: 10.1016/j.
giec.2012.10.006, indexed in Pubmed: 23168125.
